David Avigan, M.D.
Dr. Avigan is Assistant Professor of Medicine, Harvard Medical School, aand Director of Hematological Malignancies and Bone Marrow Transplantation, Beth Israel Deaconess Medical Center and Dana Farber Harvard Cancer Center, Boston, MA.
Within the last 12 months Dr. Avigan reports research support from Genzyme and Berlex.
This activity is made possible by an unrestricted educational grant from
.
Release Date: 12/06/2007
Upon completion of this Cyberounds®, you should be able to:
Identify the unique biological characteristics of AML in the elderly and their impact on response to therapy
Discuss therapeutic trials in elderly patients with AML which examine the role of aggressive and low intensity chemotherapy
Define the role of autologous and allogeneic hematopoietic transplantation in elderly patients with AML
Discuss the role of novel agents as therapy for elderly patients with AML.